Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.

Gandini S, Massi D, MandalĂ  M.

Crit Rev Oncol Hematol. 2016 Apr;100:88-98. doi: 10.1016/j.critrevonc.2016.02.001. Review.

PMID:
26895815
2.

Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.

Kakavand H, Vilain RE, Wilmott JS, Burke H, Yearley JH, Thompson JF, Hersey P, Long GV, Scolyer RA.

Mod Pathol. 2015 Dec;28(12):1535-44. doi: 10.1038/modpathol.2015.110.

3.

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.

Madore J, Vilain RE, Menzies AM, Kakavand H, Wilmott JS, Hyman J, Yearley JH, Kefford RF, Thompson JF, Long GV, Hersey P, Scolyer RA.

Pigment Cell Melanoma Res. 2015 May;28(3):245-53. doi: 10.1111/pcmr.12340.

PMID:
25477049
4.

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics.

Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, Buonincontri R, Baroni G, Nassini R, Minocci D, Cattaneo L, Tamborini E, Carobbio A, Rulli E, Deaglio S, MandalĂ  M.

Ann Oncol. 2014 Dec;25(12):2433-42. doi: 10.1093/annonc/mdu452.

PMID:
25223485
5.

Overall survival and PD-L1 expression in metastasized malignant melanoma.

Gadiot J, Hooijkaas AI, Kaiser AD, van Tinteren H, van Boven H, Blank C.

Cancer. 2011 May 15;117(10):2192-201. doi: 10.1002/cncr.25747.

Supplemental Content

Loading ...
Support Center